Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.55 |
| ▸ | GAA | P10253 | 8/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6431684 | 0.90 | MAPT (0.52) | MAPTRAB9AALDH1A1GAAKDM4E | |
| SCHEMBL6238938 | 0.90 | KMT2A (0.56) | MAPTRAB9AALDH1A1GAAKDM4E | |
| SCHEMBL7019254 | 0.87 | ALDH1A1 (0.48) | MAPTRAB9AALDH1A1GAAKDM4E | |
| SCHEMBL7052320 | 0.87 | PTPN5 (0.55) | MAPTALDH1A1GAAKDM4EHSD17B10 | |
| SCHEMBL7191192 | 0.87 | ALDH1A1 (0.60) | MAPTRAB9AALDH1A1GAAKDM4E | |
| SCHEMBL6218489 | 0.87 | HPGD (0.65) | MAPTALDH1A1GAAKDM4EHSD17B10 | |
| SCHEMBL7634269 | 0.86 | ALDH1A1 (0.49) | MAPTRAB9AALDH1A1GAAKDM4E | |
| SCHEMBL7630671 | 0.85 | ALDH1A1 (0.49) | MAPTRAB9AALDH1A1GAAKDM4E | |
| SCHEMBL7012169 | 0.83 | ALDH1A1 (0.47) | MAPTRAB9AALDH1A1GAAKDM4E | |
| SCHEMBL2775966 | 0.82 | CA12 (0.57) | MAPTRAB9AALDH1A1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | MAPT 4823/4885RAB9A 1888/4885ALDH1A1 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.